A sugar transporter regulates serum urate levels: Implications for prevention and management of hyperuricemia in gout Robert A. Terkeltaub Clinical Trials Report 22 March 2009 Pages: 83 - 85
Genetics of systemic sclerosis-associated pulmonary arterial hypertension: Recent progress and current concepts Sanjiv J. Shah OriginalPaper 22 March 2009 Pages: 89 - 96
Current developments in pediatric systemic sclerosis Ivan Foeldvari OriginalPaper 22 March 2009 Pages: 97 - 102
Is scleroderma a vasculopathy? Jo Nadine FlemingRichard A. NashStephen Mark Schwartz OriginalPaper 22 March 2009 Pages: 103 - 110
Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials Karen AuDinesh KhannaDonald P. Tashkin OriginalPaper 22 March 2009 Pages: 111 - 119
Tissue stiffness, latent TGF-β1 Activation, and mechanical signal transduction: Implications for the pathogenesis and treatment of fibrosis Boris Hinz OriginalPaper 22 March 2009 Pages: 120 - 126
Calcifying tendinitis of the shoulder: Advances in imaging and management Taco GosensDirk-Jan Hofstee OriginalPaper 22 March 2009 Pages: 129 - 134
A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout Jeannie ChaoRobert Terkeltaub OriginalPaper 22 March 2009 Pages: 135 - 140
Point: Hydroxyapatite crystal deposition is intimately involved in the pathogenesis and progression of human osteoarthritis Geraldine M. McCarthyHerman S. Cheung OriginalPaper 22 March 2009 Pages: 141 - 147
Counterpoint: Hydroxyapatite crystal deposition is not intimately involved in the pathogenesis and progression of human osteoarthritis Kenneth P. H. Pritzker OriginalPaper 22 March 2009 Pages: 148 - 153
Quality of life and quality of care for patients with gout Jasvinder A. Singh OriginalPaper 22 March 2009 Pages: 154 - 160